New drug ravulizumab aims to control rare blood disorder aHUS
NCT ID NCT07308574
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the drug ravulizumab in 20 people with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. The goal is to see if the drug improves platelet counts and kidney function over 26 weeks. All participants receive the drug, and researchers will monitor safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravulizumab
What this could lead to
If successful, this study could confirm ravulizumab as a reliable treatment to control aHUS and prevent kidney damage.
What could go wrong
This is a small, single-arm study with no placebo group, so results may not be definitive. Ravulizumab also carries risks like increased susceptibility to infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGBunkyō City, 113-8655, Japan
-
Research Site
NOT_YET_RECRUITINGHirakata-shi, 573-1191, Japan
-
Research Site
RECRUITINGIruma-Gun, 350-0495, Japan
-
Research Site
NOT_YET_RECRUITINGKyoto, 602-8566, Japan
-
Research Site
NOT_YET_RECRUITINGMatsumoto-shi, 390-8621, Japan
-
Research Site
NOT_YET_RECRUITINGMiyazaki, 889-1692, Japan
-
Research Site
RECRUITINGNagoya, 466-8650, Japan
-
Research Site
NOT_YET_RECRUITINGNara, 630-8581, Japan
-
Research Site
NOT_YET_RECRUITINGNerima-ku, 177-8521, Japan
-
Research Site
NOT_YET_RECRUITINGSapporo, 060-8638, Japan
-
Research Site
NOT_YET_RECRUITINGShinjuku-ku, 162-8666, Japan
-
Research Site
RECRUITINGTsu, 514-8507, Japan